Current therapeutic strategy for multiple myeloma

Japanese Journal of Clinical Oncology

Volumn 43, Issue 2, 2013, Pages 116-124

  Suzuki, Kenshi ^a  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

ASCT; Multiple myeloma; Renal insufficiency; SPM

Indexed keywords

BENCE JONES PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENOSUMAB; DEXAMETHASONE; DOXORUBICIN; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 2; LENALIDOMIDE; M PROTEIN; MELPHALAN; PAMIDRONIC ACID; PREDNISOLONE; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE E3; VINCRISTINE; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE PHASE RESPONSE; ANTIANGIOGENIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DESTRUCTION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CONSTIPATION; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTHERMIA; HYPOCALCEMIA; INDUCTION CHEMOTHERAPY; INFECTION; INJECTION SITE INFLAMMATION; KIDNEY DYSFUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA CELL; NEUTROPENIA; NON MELANOMA SKIN CANCER; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL; PLASMA CELL; PROGRESSION FREE SURVIVAL; RASH; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; SPINAL CORD COMPRESSION; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION;

AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHOSPHONATES; DOXORUBICIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMIDAZOLES; IMMUNOGLOBULINS; INDIVIDUALIZED MEDICINE; KIDNEY; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MELPHALAN; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; PREDNISOLONE; PYRAZINES; QUALITY OF LIFE; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; THALIDOMIDE;

EID: 84873433536     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys215     Document Type: Article

References (57)

1. de Bergsagel DE, Migliore PJ, Griffith KM. Myeloma proteins and the clinical response to Melphalan Therapy. Science 1965;148:376-7.
2. Salmon SC, Shadduck RK, Schilling A. Intermittent high dose prednisone therapy for multiple myeloma. Cancer Chemother Rep 1967;51:179-87.
3. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-85.
4. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
5. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
6. Hideshima T, Bradner JE, Chauhan D, Anderson KC. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res 2005;11:8530-3.
7. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
8. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-9.
9. Jagannath S, Durie BG, Wolf JL, et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009;146:619-26.
10. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012;30:2946-55.
11. Jakubowiak AJ, Kendall T, Al-Zoubi A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009;27:5015-22.
12. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337-41.
13. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-82.
14. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
15. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239-47.
16. San Miguel JF. Continued Overall Survival Benefit after 5 years' Follow-up with Bortezomib-melphalan-prednisone (VMP) Versus melphalan-prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and no Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. 53rd Annual Meeting of the American Society of Hematology 2011. Abstract 476.
17. Iida S, Ando K, Suzuki K, et al. A phase I/II study of VMP as initial treatment for multiple myeloma in Japan. Rinsho Ketsueki 2012;53:1122.
18. Niesvizky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 2008;143:46-53.
19. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-46.
20. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010;28:2612-24.
21. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-40.
22. Moreau P, Coiteux V, Hulin C, et al. Prospective comparison of subcutaneous to intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008;93:1908-11.
23. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012;97:442-50.
24. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118:1231-8.
25. Cavo M, Pantani L, Petrucci MT, et al. Bortezomibthalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9-19.
26. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-85.
27. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752-8.
28. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;(Suppl. 1):S13-9.
29. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9.
30. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26:2326-35.
31. Lopez-Girona A, Heintel D, Zhang LH, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011;154:325-36.
32. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
33. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42.
34. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52.
35. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
36. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303-17.
37. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010;126:239-46.
38. Dunstan C, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007;4:42-55.
39. Palumbo A, Anderson K, et al. Multiple myeloma. N Engl J Med 2011;364:1046-60.
40. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289-94.
41. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788-93.
42. Suzuki K. Discovery research on the effects of giving continuity to the administration of bortezomib in maintenance therapy to target of relapsed and refractory multiple myeloma. J New Rem Clin 2012;61:1259-69.
43. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-67.
44. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782-91.
45. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770-81.
46. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69.
47. Badros AZ. Lenalidomide in myeloma-a high-maintenance friend. N Engl J Med 2012;366:1836-8.
48. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764-7.
49. Armeson KE, Hill EG, Costa LJ. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2012; doi:10.1038/ bmt.2012.173.
50. Taverna C, Voegeli J, Trojan A, et al. Effective response with bortezomib retreatment in relapsed multiple myeloma-a multicentre retrospective survey in Switzerland. Swiss Med Wkly 2012;142:w13562.
51. Dimopoulos MA, Hussein M, Swern AS, et al. Long-term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len{thorn}Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM). 53rd Annual Meeting of the American Society of Hematology 2011. Abstract 2929.
52. Reece DE, Masih-Khan E, Goswami RS, et al. Incidence and Characteristics of Secondary Myelodysplastic Syndrome Developing during Lenalidomide-based Regimens in Relapsed and/or refractory Multiple Myeloma Patients. 53rd Annual Meeting of the American Society of Hematology 2010. Abstract 1877.
53. Abe Y, Miyazaki K, Suzuki K, et al. Therapy-related myelodysplastic syndrome/acute myeloid leukemia in patients with multiple myeloma. Rinsho Ketsueki 2012;52:1264.
54. Blade J, Fernández-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889-93.
55. Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010;34:1395-7.
56. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in MM according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519-29.
57. Abe Y, Muto M, Nieda M, et al. Clinical and immunological evaluation of zoledronate-activated V9 T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009;37:956-968.